2
Clinical Trials associated with Epoetin alfa biosimilar(Apotex, Inc.) / Not yet recruitingPhase 3 A phase III, randomized, assessor-blinded, active-controlled, multicenterstudy of the efficacy and safety of APO-EPO as compared to Procrit® when given subcutaneously to patients with anemia of chronic kidney disease stage 5D who are currently not on epoetin replacement therapy
/ Not yet recruitingNot Applicable A phase III, randomized, open-label, active-controlled, multicenter, correction phase study of the efficacy, safety, pharmacokinetics, and pharmacodynamics of APO-EPO (epoetin alfa) as compared to Epogen®/Procrit® when given subcutaneously to patients with anemia and chronic kidney disease not yet on hemodialysis
100 Clinical Results associated with Epoetin alfa biosimilar(Apotex, Inc.)
100 Translational Medicine associated with Epoetin alfa biosimilar(Apotex, Inc.)
100 Patents (Medical) associated with Epoetin alfa biosimilar(Apotex, Inc.)
100 Deals associated with Epoetin alfa biosimilar(Apotex, Inc.)